Difference between revisions of "The Future of R&D in Pharmaceutical Industry in 2025"

From ScenarioThinking
Jump to: navigation, search
Line 8: Line 8:
 
<br><br>
 
<br><br>
 
==Scenarios.==
 
==Scenarios.==
 +
<br>Ruth- you left the Radical Evolution book here!  Here is a link to it: http://www.garreau.com/main.cfm?action=book&id=2 , The Pain VAccine that I mentioned is here: http://www.wired.com/medtech/health/news/2003/10/60768  and the case I mentioned in functional foods to tumeric http://www.annalsofian.org/article.asp?issn=0972-2327;year=2008;volume=11;issue=1;spage=13;epage=19;aulast=Mishra<br>
 +
 +
Good Luck! - D
 
<br><br>
 
<br><br>
 
To be added<br><br>
 
To be added<br><br>
 +
 
==Research Questions.==
 
==Research Questions.==
  

Revision as of 15:40, 29 September 2009

EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu

Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.

Scenarios.


Ruth- you left the Radical Evolution book here! Here is a link to it: http://www.garreau.com/main.cfm?action=book&id=2 , The Pain VAccine that I mentioned is here: http://www.wired.com/medtech/health/news/2003/10/60768 and the case I mentioned in functional foods to tumeric http://www.annalsofian.org/article.asp?issn=0972-2327;year=2008;volume=11;issue=1;spage=13;epage=19;aulast=Mishra

Good Luck! - D

To be added

Research Questions.

  • Move to emerging markets (subquestions: what is government stance, how is local infrastructure (ie. can you get the drugs to the people?)?
  • What are regulatory issues regarding local registration of the drug?
  • No more blockbusters, even focus on generics, or are there still enough other diseases to cure without simply incrementally improving existing drugs?
  • Generics vs. Patents? What will the IP landscape be?

Driving forces.

Edited existing ones

Increasing potential to grow based on new available technology
Struggling old world economy
Increasing Empowerment of Consumers in Healthcare System
Continuously growing demand for new medical applications
The increasing gap between developed, emerging and poor economies
The increasing globalization of markets
Power of the United Nations
Legal Restrictions for Biotech increasing in certain countries, decreasing in others


Added new ones

IP rights
Logistics/Distribution
Illnesses of global importance/Pandemics
Research budget in pharmaceutical industry
Effect of development of health care system in emerging market countries to existing pharmaceutical industry
Unification of regulatory approval
Increasing Competitiveness through innovation in biotechnology
Changing business models for pharmaceutical industry


Resources